Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database [3]

Journal of Acquired Immune Deficiency Syndromes

Volumn 43, Issue 4, 2006, Pages 501-503

  Zhou, Jialun ^a   Phanupak, Praphan ^b   Kiertiburanakul, Sasisopin ^c   Ditangco, Rossana ^d   Kamarulzaman, Adeeba ^e   Pujary, Sanjay ^f  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^e UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^f Ruby Hall Clinic ^*  (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; DATA BASE; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; ETHNOLOGY; GASTROINTESTINAL DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIPODYSTROPHY; LIVER FAILURE; LIVER TOXICITY; NAUSEA AND VOMITING; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG THERAPY, COMBINATION; EXANTHEMA; HIV INFECTIONS; HIV-1; HUMANS; LIVER DISEASES; NEVIRAPINE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33750953308     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000243109.33759.81     Document Type: Letter

References (15)

1. WHO UNAIDS. Treating 3 Million by 2005: Making It Happen - The WHO Strategy. Geneva; WHO; 2003.
2. Kumarasamy N, Vallabhaneni S, Flanigan TP, et al. Rapid viral load suppression following generic highly active antiretroviral therapy in Southern Indian HIV-infected patients. AIDS. 2005;19:625-627.
3. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363:1253-1263.
4. Pujari SN, Patel AK, Naik E, et al. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immune Defic Syndr. 2004;37:1566-1569.
5. Kumarasamy N, Solomon S, Chaguturu SK, et al. The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS. 2003;17:2267-2269.
6. van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. 2003;17:987-999.
7. Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine- or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35:182-189.
8. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998;279:930-937.
9. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423-1430.
10. Ananworanich J, Moor Z, Siangphoe U, et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS. 2005;19:185-192.
11. Ho TT, Wong KH, Chan KC, et al. High incidence of nevirapine-associated rash in HIV-infected Chinese. AIDS. 1998;12:2082-2083.
12. Zhou J, Kumarasamy N, Ditangco R, et al. The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr. 2005;38:174-179.
13. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS. 2005;19:97-99.
14. Ogedegbe AO, Sulkowski MS. Antiretroviral-associated liver injury. Clin Liver Dis. 2003;7:475-499.
15. Law WP, Dore GJ, Duncombe CJ, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS. 2003;17:2191-2199.